Fulcrum Explores Sale Amid FDA Setback for Sickle Cell Drug
Decision brief
Answer first · skim in under a minute
Fulcrum Therapeutics is reportedly exploring strategic alternatives, including a potential sale, after the FDA raised concerns about its lead sickle cell drug, pociredir. This move follows similar market withdrawals for other sickle cell treatments.
Fulcrum Therapeutics said on 1 June 2026 it would stop developing pociredir for sickle cell disease and review strategic options that could include a sale. The decision follows FDA feedback on PRC2 malignancy risk. It lands in a field still absorbing the 2024 Oxbryta withdrawal.
Contents10 sections
Key Takeaways
- On 1 June 2026 Fulcrum discontinued pociredir and opened a strategic alternatives review after FDA end-of-phase minutes dated around 28 May 2026.
- FDA linked heightened concern to secondary hematologic malignancies seen with Tazverik (tazemetostat), a PRC2 inhibitor withdrawn globally in March 2026.
- As of 31 March 2026 Fulcrum held $333.3 million in cash, cash equivalents, and marketable securities.
- Oxbryta (voxelotor) remains a separate case: Pfizer withdrew it worldwide in September 2024 after vaso-occlusive crisis and fatal-event imbalances.
What did Fulcrum announce on 1 June 2026?
In a GlobeNewswire release, Fulcrum said it discontinued the pociredir sickle cell program and started a comprehensive review of strategic alternatives to maximize stockholder value. Options may include a merger, acquisition, business combination, or other deals involving the company or its assets.
The company also said it is cutting operating expenses and preserving capital. It gave no timeline for finishing the review and said it would not update markets until the board acts or the process ends.
Why did the FDA block a path for pociredir?
Fulcrum said it received FDA meeting minutes on 28 May 2026 from recent end-of-phase talks. The minutes flagged benefit-risk concerns in sickle cell disease after an unexpectedly high rate of secondary hematologic malignancies with Tazverik, another PRC2 inhibitor withdrawn in March 2026.
Fulcrum argued that EED (pociredir) and EZH2 (tazemetostat) play different biological roles. FDA still concluded that pharmacological targeting of the PRC2 complex carries equivalent malignancy risk. The agency also cited Fulcrum’s previously disclosed preclinical malignancy observations and left no viable regulatory path for further clinical development.
Those facts are also reflected in Fulcrum’s SEC Form 8-K filing for the June 1 announcement.
How does the Oxbryta withdrawal fit this story?
Oxbryta is not Fulcrum’s drug. Pfizer voluntarily withdrew all lots of Oxbryta worldwide in September 2024 and stopped related trials. The FDA safety alert said postmarketing data showed more vaso-occlusive crises and more deaths on Oxbryta than on placebo in cited studies.
For patients and investors, Oxbryta’s exit is context, not the same regulatory theory as Fulcrum’s PRC2 malignancy feedback. Both events do raise the bar for sickle cell small-molecule risk narratives.
What clinical claims remain from PIONEER?
Before the stop, Fulcrum said pociredir showed dose-dependent fetal hemoglobin (HbF) rises in the PIONEER Phase 1b trial, with generally well-tolerated exposure up to three months in the 12 mg and 20 mg cohorts and no treatment-related serious adverse events reported in that disclosure. Those efficacy and safety statements are company-reported and are now moot for a registrational path after the FDA feedback.
- Announcement date: 1 June 2026
- FDA minutes received: 28 May 2026
- Cash (31 March 2026): $333.3 million
- Ticker: Nasdaq FULC
- Oxbryta withdrawal: September 2024
What should investors watch next?
Watch for restructuring depth, cash burn, and whether a buyer emerges for remaining assets or platform technology. A later 8-K discussed engaging Leerink Partners for the strategic process. Do not treat “sale” as a done deal until a signed transaction is disclosed. Sickle cell advocates will also watch whether other HbF-inducing small molecules face similar PRC2 class questions in 2026 reviews.
What remains unproven?
Independent confirmation that EED inhibitors share the same human malignancy risk as EZH2 inhibitors is a regulatory conclusion here, not a fully adjudicated class label across all PRC2 drugs. Fulcrum also said no new clinical safety signals were seen with pociredir to date. That company claim does not override the FDA’s “no viable path” stance. Readers should separate Oxbryta’s 2024 vaso-occlusive risk story from Fulcrum’s 2026 PRC2 malignancy feedback.
Related NovaPharma coverage
- Gilead Hepcludex FDA Approval for Hepatitis D
- Eli Lilly Verve Heart Drug Data
- FDA Pulmonary Tuberculosis Drug Development Guidance
Frequently Asked Questions
Did Fulcrum discontinue pociredir or Oxbryta?
Fulcrum discontinued pociredir, its EED/PRC2 program for sickle cell disease, after FDA feedback in May–June 2026. Oxbryta (voxelotor) is a separate Pfizer product voluntarily withdrawn in September 2024.
Why is Fulcrum reviewing a sale or merger?
After ending pociredir, Fulcrum started a review of strategic alternatives that may include a merger, acquisition, business combination, or other transactions, and moved to cut operating expenses.
What cash balance did Fulcrum report?
As of March 31, 2026, Fulcrum reported $333.3 million in cash, cash equivalents, and marketable securities in its June 1, 2026 announcement.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Oxbryta.
Unlock full calendar →Fulcrum pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
